SCNI Scinai: רווח למניה בשנים עשר החודשים האחרונים

Scinai Immunotherapeutics (SCNI) is developing a flexible nanobody platform for the rapid combat of viruses. Earnings per share over the last four quarters on GURU.Markets illustrate financial stability, where -2.89 defines the current value of the metric. Despite a temporary profit deficit during the transition to a CDMO model, Scinai Immunotherapeutics aims for leadership in biomanufacturing and the development of its own immune therapeutics.
פילוחים אנליטיים ודוחות נתונים של חברת BiondVax Pharmaceuticals (SCNI)

Scinai Immunotherapeutics (SCNI) generates revenue through the creation of innovative biologics to combat infections and inflammation. By analyzing earnings per share (EPS) over the last 12 months, an investor assesses the net income allocated to a single common share. This indicator strips the financial result of the influence of the total shares outstanding. The trend in earnings per share over the last 12 months reveals the actual efficiency of the capitalization of developments. Steady growth in this metric confirms the fundamental stability of the assets.